PDT Partners’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-21,098
| Closed | -$2.34M | – | 630 |
|
|
2025
Q2 | $2.34M | Sell |
21,098
-1,502
| -7% | -$160K | 0.13% | 269 |
|
|
2025
Q1 | $2.53M | Buy |
22,600
+1,496
| +7% | +$154K | 0.18% | 192 |
|
|
2024
Q4 | $1.95M | Sell |
21,104
-3
| -0% | -$270 | 0.17% | 207 |
|
|
2024
Q3 | $1.77M | Buy |
+21,107
| New | +$1.61M | 0.16% | 238 |
|
|
2023
Q2 | – | Sell |
-9,200
| Closed | -$763K | – | 606 |
|
|
2023
Q1 | $763K | Buy |
9,200
+5,751
| +167% | +$476K | 0.1% | 318 |
|
|
2022
Q4 | $296K | Buy |
+3,449
| New | +$273K | 0.05% | 486 |
|
|
2022
Q2 | – | Sell |
-7,700
| Closed | -$458K | – | 1031 |
|
|
2022
Q1 | $458K | Buy |
+7,700
| New | +$492K | 0.04% | 613 |
|
|
2021
Q4 | – | Sell |
-6,500
| Closed | -$454K | – | 925 |
|
|
2021
Q3 | $454K | Sell |
6,500
-65,300
| -91% | -$4.59M | 0.03% | 497 |
|
|
2021
Q2 | $4.94M | Buy |
71,800
+1,500
| +2% | +$100K | 0.33% | 74 |
|
|
2021
Q1 | $4.54M | Sell |
70,300
-4,483
| -6% | -$289K | 0.33% | 82 |
|
|
2020
Q4 | $4.36M | Sell |
74,783
-30,317
| -29% | -$1.83M | 0.29% | 159 |
|
|
2020
Q3 | $6.64M | Buy |
+105,100
| New | +$7.29M | 0.44% | 77 |
|
|
2020
Q2 | – | Sell |
-129,300
| Closed | -$9.67M | – | 720 |
|
|
2020
Q1 | $9.67M | Buy |
+129,300
| New | +$8.93M | 0.77% | 12 |
|
|
2019
Q2 | – | Sell |
-360,740
| Closed | -$23.5M | – | 431 |
|
|
2019
Q1 | $23.5M | Buy |
360,740
+68,691
| +24% | +$4.57M | 1.33% | 12 |
|
|
2018
Q4 | $18.3M | Buy |
292,049
+35,631
| +14% | +$2.49M | 1.02% | 18 |
|
|
2018
Q3 | $19.8M | Buy |
256,418
+18
| +0% | +$1.36K | 0.82% | 30 |
|
|
2018
Q2 | $18.2M | Buy |
256,400
+31,800
| +14% | +$2.25M | 0.69% | 35 |
|
|
2018
Q1 | $16.9M | Sell |
224,600
-23,400
| -9% | -$1.86M | 0.57% | 50 |
|
|
2017
Q4 | $17.8M | Buy |
248,000
+86,940
| +54% | +$6.6M | 0.52% | 63 |
|
|
2017
Q3 | $13M | Sell |
161,060
-16,140
| -9% | -$1.23M | 0.43% | 78 |
|
|
2017
Q2 | $12.5M | Buy |
177,200
+85,577
| +93% | +$5.69M | 0.5% | 52 |
|
|
2017
Q1 | $6.22M | Buy |
91,623
+2,823
| +3% | +$199K | 0.33% | 123 |
|
|
2016
Q4 | $6.36M | Buy |
88,800
+7,600
| +9% | +$565K | 0.42% | 62 |
|
|
2016
Q3 | $6.42M | Buy |
81,200
+14,023
| +21% | +$1.14M | 0.38% | 119 |
|
|
2016
Q2 | $5.6M | Sell |
67,177
-523
| -0.8% | -$46.4K | 0.44% | 109 |
|
|
2016
Q1 | $6.22M | Buy |
67,700
+32,195
| +91% | +$2.9M | 0.39% | 56 |
|
|
2015
Q4 | $3.59M | Buy |
35,505
+15,405
| +77% | +$1.6M | 0.49% | 69 |
|
|
2015
Q3 | $1.97M | Sell |
20,100
-254,292
| -93% | -$28.2M | 0.04% | 458 |
|
|
2015
Q2 | $32.1M | Buy |
274,392
+167,158
| +156% | +$18.3M | 0.84% | 13 |
|
|
2015
Q1 | $10.5M | Buy |
+107,234
| New | +$10.9M | 0.26% | 84 |
|
|
2014
Q4 | – | Sell |
-555,550
| Closed | -$59.1M | – | 808 |
|
|
2014
Q3 | $59.1M | Buy |
555,550
+226,210
| +69% | +$22.2M | 1.5% | 3 |
|
|
2014
Q2 | $27.3M | Buy |
329,340
+36,440
| +12% | +$2.84M | 0.73% | 13 |
|
|
2014
Q1 | $20.8M | Buy |
292,900
+285,178
| +3,693% | +$22.4M | 0.5% | 36 |
|
|
2013
Q4 | $580K | Buy |
7,722
+700
| +10% | +$48.7K | 0.07% | 357 |
|
|
2013
Q3 | $441K | Sell |
7,022
-188,450
| -96% | -$11.3M | 0.01% | 1093 |
|
|
2013
Q2 | $10M | Buy |
+195,472
| New | +$10.2M | 0.25% | 88 |
|
Other funds holding GILD
PDT Partners's GILD Position: Q3 2025 in Review
PDT Partners sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 21,098 shares — an estimated $2.34M sold.
PDT Partners first reported a position in GILD in Q2 2013 and held it in 36 quarters. The position peaked at $59.1M in Q3 2014. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.
- PDT Partners reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
- PDT Partners sold 21,098 Gilead Sciences shares in Q3 2025, an estimated $2.34M.
- PDT Partners first reported a position in Gilead Sciences in Q2 2013 and held it in 36 quarters.
- PDT Partners's Gilead Sciences position peaked at $59.1M in Q3 2014.
- 2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.
Based on PDT Partners's 13F filing for Q3 2025, filed 17 Nov 2025.